1. Search Result
Search Result
Results for "

folate receptors

" in MedChemExpress (MCE) Product Catalog:

25

Inhibitors & Agonists

10

Biochemical Assay Reagents

3

Inhibitory Antibodies

4

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13728

    ZD 9331; BGC9331

    Thymidylate Synthase Cancer
    Plevitrexed (ZD 9331; BGC 9331) is an orally active and potent thymidylate synthase (TS) inhibitor with a Ki of 0.44 nM. Plevitrexed is taken up via the α-folate receptor as well as the reduced folate carrier. Plevitrexed is used for gastric cancer in clinical . Plevitrexed is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Plevitrexed
  • HY-P99612

    MORAb-202

    Antibody-Drug Conjugates (ADCs) Cancer
    Farletuzumab ecteribulin (MORAb-202) is an antibody-drug conjugate (ADC), consisting of the humanized anti-human folate receptor alpha (FRA) antibody Farletuzumab (HY-P99153) conjugated via reduced interchain disulfide bonds to Mal-PEG2-Val-Cit-PAB-eribulin. Farletuzumab ecteribulin has a agent-to-antibody ratio of 4.0. Farletuzumab ecteribulin is highly cytotoxic to FRA-positive cells in vitro. Farletuzumab ecteribulin has potent antitumor activity.
    Farletuzumab ecteribulin
  • HY-10822A

    BGC 945 trisodium; Idetrexed trisodium; CB 300945 trisodium

    Thymidylate Synthase Cancer
    ONX 0801 (BGC 945) trisodium is a thymidylate synthase (TS) inhibitor, targeted to α-folate receptor–overexpressing tumors .
    ONX 0801 trisodium
  • HY-147699

    Antifolate Cancer
    FRα-IN-1 (Compound 4) is a tumor-targeting agent. FRα-IN-1 shows selective anticancer activity towards folate receptors (FRα and FRβ) expression cells .
    FRα-IN-1
  • HY-115873

    PROTACs Cancer
    Folate-MS432, a PROTAC, is capable of degrading MEKs in a folate receptor-dependent manner in cancer cells.
    Folate-MS432
  • HY-144009

    Liposome Cancer
    DSPE-PEG-Folate, MW 3350 is a PEG derivative containing folic acid. DSPE-PEG-Folate has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate form micelles/lipid bilayer and can be used to targeted drug delivery system research .
    DSPE-PEG-Folate, MW 3350
  • HY-W440888

    Liposome Others
    DSPE-PEG-Folate, MW 2000 is a PEG derivative containing folic acid. DSPE-PEG-Folate, MW 2000 has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate, MW 2000 form micelles/lipid bilayer and can be used to targeted drug delivery system research.
    DSPE-PEG-Folate, MW 2000
  • HY-W440890

    Liposome Cancer
    DSPE-PEG-Folate, MW 5000 is a PEG derivative containing folic acid. DSPE-PEG-Folate, MW 5000 has a targeting effect and bind to folate receptors in cancer cells. DSPE-PEG-Folate, MW 5000 form micelles/lipid bilayer and can be used to targeted drug delivery system research .
    DSPE-PEG-Folate, MW 5000
  • HY-155880

    mPEG-NH2 (MW 350)

    Liposome Cancer
    mPEG-amine (MW 350) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 350)
  • HY-155881

    mPEG-NH2 (MW 550)

    Liposome Cancer
    mPEG-amine (MW 550) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 550)
  • HY-155882

    mPEG-NH2 (MW 750)

    Liposome Cancer
    mPEG-amine (MW 750) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 750)
  • HY-155883

    mPEG-NH2 (MW 3400)

    Liposome Cancer
    mPEG-amine (MW 3400) can synthesize folate-conjugated polymer micelles for encapsulation of anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 3400)
  • HY-155884

    mPEG-NH2 (MW 4000)

    Liposome Cancer
    mPEG-amine (MW 4000) can be used to synthesize folate-conjugated polymer micelles for encapsulating anticancer agent 9-nitrocamptothecin (HY-16560). folate-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    mPEG-amine (MW 4000)
  • HY-P99225

    M9346A

    Antifolate Cancer
    Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research .
    Mirvetuximab
  • HY-128939

    Antifolate Cancer
    EC0488 is used to synthesize EC0531 with folate receptor (FR)-specific and anti-tumor activities .
    EC0488
  • HY-W115607

    Poly(ethylene glycol)-bis-amine (MW 8000)

    Liposome Cancer
    PEG-bis-amine (MW 8000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent 9-nitrocamptothecin HY-16560 (HY-16560). Folic acid-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    PEG-bis-amine (MW 8000)
  • HY-W591632

    Poly(ethylene glycol)-bis-amine (MW 1000)

    Liposome Cancer
    PEG-bis-amine (MW 1000) synthesizes folate-conjugated polymeric micelles for encapsulation of the anticancer agent 9-nitrocamptothecin HY-16560 (HY-16560). Folic acid-conjugated polymer micelles are effective carriers of insoluble anticancer drugs, which can avoid macrophages and play a role in endocytosis of tumor cells mediated by folate receptors (FR).
    PEG-bis-amine (MW 1000)
  • HY-114306

    Antifolate Cancer
    EC0489, a conjugate of folic acid and desacetyl vinblastine hydrazide, is a high-affinity ligand for the folate receptor (FR). Refractory or metastatic Tumor . Small molecule-agent conjugate (SMDC) .
    EC0489
  • HY-10822

    BGC 945; ONX-0801

    Thymidylate Synthase Others
    Idetrexed is a thymidylate synthase inhibitor specifically transported into alpha-folate receptor (alpha-FR)-overexpressing tumors. BGC 945 inhibited thymidylate synthase with a Ki of 1.2 nmol/L .
    Idetrexed
  • HY-13615A

    Fluorescent Dye Cancer
    EC-17 (disodium salt) is a folate receptor alpha (FRα) targeting contrast agent with fluorescent properties in the visible light spectrum. The peak excitation and emission wavelengths of EC-17 are 470/520 nm.
    EC-17 disodium salt
  • HY-P99153

    MORAb-003

    Antibiotic Cancer
    Farletuzumab (MORAb-003) is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab is a humanized monoclonal antibody with high affinity for FRα. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer .
    Farletuzumab
  • HY-D1716

    Fluorescent Dye Cancer
    S0456 is a near-infrared (NIR) fluorescent dye that can be used for synthesize Pafolacianine (HY-139579). S0456 binds to the folate receptor (FR). S0456 can be used as a tumor-specific optical imaging agent. The excitation wavelength is 788 nM and emission wavelength is 800 nM .
    S0456
  • HY-132258

    IMGN853

    Antibody-Drug Conjugates (ADCs) Cancer
    Mirvetuximab soravtansine (IMGN853) is an antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
    Mirvetuximab soravtansine
  • HY-132258A

    IMGN853 (solution)

    Antibody-Drug Conjugates (ADCs) Cancer
    Mirvetuximab soravtansine (IMGN853) solution is an antibody drug-conjugate (ADC) consisting of the cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A. Mirvetuximab soravtansine selectively binds to folate receptor 1 (FOLR1). Mirvetuximab soravtansine has an anti-proliferative effect via growth arrest and augmented DNA damage .
    Mirvetuximab soravtansine (solution)
  • HY-148194

    Drug-Linker Conjugates for ADC Cancer
    SC239 is a cleavable 2-aminophenyl hemiasterlin agent-linker. SC239 can be as the agent-linker for ADC . SC239 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    SC239

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: